Sutro Biopharma: Clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs). Sutro has two wholly owned ADCs in the clinic—STRO-002, a folate receptor alpha (FolRα)-targeting ADC, in clinical studies for ovarian and endometrial cancers; and STRO-001, a CD74-targeting ADC, in clinical studies for B-cell malignancies. STRO-003, an optimally designed ROR1-targeting ADC, is anticipated to be the next proprietary product candidate to move into clinical studies. Sutro also has high value collaborations with BMS (BCMA ADC), Merck (cytokine derivatives), EMD Serono (MUC1-EGFR bispecific ADC), and Astellas (immunostimulatory antibody-drug conjugates or iADCs).